Patent And The Law – Licensing Of Patent In India

Patent licensing is a concept that provides that patent holder can further delegate his/her rights to a person who can further use it according to the patent holder and take his invention forward and in return pay royalty or remuneration to the holder.

PATENT LICENSING

A patent license is a right granted to a person to protect and authorize a patent to that person so that nobody can sell, use, or exploit his patent. Such use or selling can only be done by the consent of the patent holders only and so licensing comes into the key role. It is also a tool that can transfers the exclusive rights over the patent from one person to another before the expiration of such patent. Also, there are few conditions upon which the license holder may delegate his authority to the licensee.

[Image Source: Shutterstock]

TRIPS (TRADE RELATED ASPECTS TO INTELLECTUAL PROPERTY RIGHTS)

Doha conference 2001 held by WTO necessitated the medicine over IPR. It was decided clearly that the medicines are provided at cheaper rates for protecting the public health and the country’s member to it may decide on their own about the terms and conditions regarding the same.

In India, the idea of Compulsory Licensing is in play. It alludes to a permit given to a person involved with assembling, sell or utilize the item or product which has been conceded a patent without the consent of the proprietor. The conditions for compulsory licensing is secured under section 84 and 92 of the Indian Patent Act 1970 which expresses that:

Compulsory licensing will be allowed on the accompanying grounds (Section 84):

  • That the reasonable prerequisites of the general population regarding the licensed creation have not been fulfilled or,
  • That the protected development isn’t accessible to people in general at a sensibly reasonable cost or,
  • That the protected development isn’t worked in the region of India.

Segment 92 of Patent Act, 1970, manages different grounds on which the compulsory licensing will be allowed. These are unique arrangements or special provisions for compulsory licensing on warnings by Central Government. Government awards necessary licenses on the accompanying grounds:

  • For trades, on the off chance that the item is utilized for sending out to another nation, at that point government can allow licenses yet this is just in uncommon conditions.
  • In circumstances of national emergency or if there is a public crisis, where the item is required in earnest conditions like in war or in wellbeing.

Preferences for according the compulsory license:

  • License is significant for giving moderate items, for example, medications and medications to people in general. It guarantees that such a creation is used for the public at great as opposed to being held with the patentee, in this manner, demonstrating advantageous for the immature and the non-industrial nations or underdeveloped nations.
  • The compulsory license has arrangements for simultaneously remunerating the proprietor of the patent so it keeps on going about as a motivating force alongside the item being utilized by the general population.
  • In situations where there isn’t any money related quality of the patentee for creation of the development, the equivalent can be conceded to the licensee to do the creation.

Natco Pharma Ltd. is the primary organization to file a petition for necessary authorizing for delivering the generic form of Bayer’s Corporation’s licensed medication Nexavar. This medication was utilized in the treatment related to kidney and liver disease. The patent office in 2012 allowed the obligatory permit/ compulsory license to Natco Pharma for a similar medication for the explanation that general society didn’t approach this medication at moderate cost and the protected innovation was not worked in India. They expressed that all the 3 points of section 84 were satisfied that,

  • The sensible necessities of the general population were not satisfied
  • That it was not accessible at a reasonable cost
  • Licensed innovation was not worked around in India.

Thus, Natco applied for the necessary license under S. 84 of the Patent Act for Bayer’s licensed medication Nexavar. Nexavar was accessible by the Bayer Corporation for $ 6299 for a month’s course. Natco Pharma recommended that a similar medication would be accessible by the name of Sorafenib Tosylate for just $196. It was recommended that it would profit the entire public of India which is in millions. The administration ruled for the overall population wellbeing and conceded the mandatory license to Natco Pharma.

For another situation of compulsory license in India, Lee Pharma, a Hyderabad based Indian pharma organization, documented an application for a necessary license for the patent covering AstraZeneca’s diabetes the board drug Saxagliptin. The grounds affirmed by Lee Pharma were that:

  • The patentee has neglected to meet the sensible prerequisites of general society,
  • The protected creation isn’t accessible to general society at a sensibly moderate cost, and
  • The protected creation isn’t worked in India.

Notwithstanding, all the three grounds of Lee Pharma were dismissed by the Controller General, and the Compulsory license application was denied on the ground that Lee Pharma neglected to exhibit what the sensible prerequisite of people, in general, was as for Saxagliptin. The Controller General likewise expressed that Lee Pharma neglected to show the specific number of patients being recommended the licensed medication and the number of them couldn’t acquire it because of its non-accessibility and thusly it was hard to hold if producing in India was vital.

Author: Niharika Singh, a 5th-year student of GGSIPU University, an intern at Khurana & Khurana, Advocates and IP Attorneys. In case of any queries please contact/write back to us at aishani@khuranaandkhurana.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

three × 3 =

Archives

  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010